Davis Polk advised the joint book-running managers in the offering.Editas Medicine, Inc. (Nasdaq: EDIT) announced the pricing of an underwritten offering of 12,500,000 shares of its common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
